Filters
The pivotal phase III CHAPTER-GIST-301 trial presented at ASCO 2021 demonstrated the potential of pimitespib, a novel oral inhibitor of heat shock protein 90 (HSP90), for the treatment of individuals with advanced gastrointestinal stromal tumours (GISTs) refractory to standard treatment (ie, imatinib, sunitinib, and regorafenib).
Tofacitinib shows consistent efficacy and safety in the treatment of patients with ulcerative colitis (UC) across body mass index (BMI) categories, according to data from the OCTAVE studies.
Use of a bacterial lysate containing Escherichia coli and Enterococcus faecalis does not appear to benefit irritable bowel syndrome (IBS) patients across all subtypes, although it shows an efficacy signal in those with diarrhoea-predominant IBS, according to a phase IV study.
Hepatic arterial infusion chemotherapy consisting of a FOLFOX* regimen (HAIC-FO) showed superior efficacy over sorafenib in the first-line treatment of locally advanced or unresectable hepatocellular carcinoma (HCC), according to the findings of the phase III FOHAIC-1 study presented at ASCO 2021.
Treatment with tislelizumab led to a significantly improved overall survival (OS) in patients with advanced or metastatic oesophageal squamous cell carcinoma (ESCC) compared with chemotherapy in the second-line setting, according to the RATIONALE 302* study presented at ASCO 2021.
An analysis of patients with moderately to severely active ulcerative colitis (UC) highlighted the general safety of the oral sphingosine-1-phosphate (S1P) receptor 1 and 5 modulator ozanimod, according to a presentation at Digestive Disease Week 2021.
Among women with intrahepatic cholestasis of pregnancy (ICP), ursodeoxycholic acid (UDCA) treatment was associated with a reduction in the risk of composite adverse perinatal outcomes of stillbirth and preterm birth (PTB), a meta-analysis suggests.
Complete suppression of hepatitis B virus (HBV) has increased from 91.9 percent at tenofovir alafenamide (TAF) switch following use of entecavir for an average of 6 months to 97.2 percent at 96 weeks later, according to a study.
Exposure to secondhand smoke in childhood and adulthood appears to elevate the risk of adult nonalcoholic fatty liver, reveals a study, noting that the prevention of passive smoking should begin as early as possible and be maintained throughout lifetime.
The increasing use of social media and online reviews has made it easier for patients to comment publicly—on Facebook and Google reviews, for instance—on the care they receive. Positive comments are heartening for any healthcare professional to read.
